Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Diagnostics Corp.

www.roche-diagnostics.us

Latest From Roche Diagnostics Corp.

News We’re Watching: May Health PCOS Treatment Shows Promise, Roche Adds Alzheimer’s Assays, Luciole Buys Spiegelberg

This week, May Health’s Ovarian Rebalancing showed promise as a treatment for polycystic ovarian syndrome; a trial of CathWorks’ FFRangio System launched; Roche introduced new assays for Alzheimer’s Disease; Early Health settled data breach allegations; and Boston Scientific added two new board members.

Commercial Regulation

Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.

Artificial Intelligence Business Strategies

News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use

This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.

Commercial Policy

Minute Insight: Quest Diagnostics To Acquire Haystack Oncology For $300M In Cash

Quest Diagnostics will buy liquid biopsy start-up Haystack Oncology for a total of $450m with plans to launch a cancer-detection test in 2024.

Minute Insights M & A
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
UsernamePublicRestriction

Register